News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
The CDCCs are strategically positioned in regions identified as high-impact areas
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Launches collaborative centre for translational research in head and neck cancer
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Subscribe To Our Newsletter & Stay Updated
